Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. Neuro Oncol 2015 Nov;17(11):1538-9
Date
09/13/2015Pubmed ID
26361983Pubmed Central ID
PMC4648309DOI
10.1093/neuonc/nov163Scopus ID
2-s2.0-84946558454 (requires institutional sign-in at Scopus site) 6 CitationsAuthor List
Boxerman JL, Schmainda KM, Zhang Z, Barboriak DPAuthor
Kathleen M. Schmainda PhD Professor in the Biophysics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Angiogenesis InhibitorsBevacizumab
Brain Neoplasms
Cerebral Cortex
Female
Glioblastoma
Humans
Magnetic Resonance Imaging
Male
